Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating reaffirmed by research analysts at SunTrust Banks, Inc. in a research report issued on Wednesday. They presently have a $82.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $95.00. SunTrust Banks, Inc.’s price objective indicates a potential upside of 26.52% from the company’s current price. SunTrust Banks also issued estimates for Sage Therapeutics’ Q4 2017 earnings at ($1.54) EPS, FY2017 earnings at ($6.63) EPS, FY2018 earnings at ($5.62) EPS, FY2019 earnings at ($4.63) EPS, FY2020 earnings at ($3.04) EPS and FY2021 earnings at ($0.10) EPS.
Other analysts have also issued research reports about the stock. BidaskClub lowered shares of Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and set a $82.00 price target on shares of Sage Therapeutics in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and set a $90.00 price target on shares of Sage Therapeutics in a research report on Friday, July 14th. Canaccord Genuity set a $110.00 price target on shares of Sage Therapeutics and gave the stock a “buy” rating in a research report on Saturday, August 5th. Finally, Cowen and Company reiterated a “buy” rating and set a $100.00 price target on shares of Sage Therapeutics in a research report on Friday, August 4th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $84.25.
Sage Therapeutics (NASDAQ SAGE) opened at 64.81 on Wednesday. The company’s market cap is $2.43 billion. Sage Therapeutics has a 1-year low of $38.30 and a 1-year high of $90.80. The stock has a 50 day moving average of $81.85 and a 200-day moving average of $74.87.
Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same period last year, the business posted ($1.08) EPS. On average, equities research analysts predict that Sage Therapeutics will post ($7.38) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “SunTrust Banks, Inc. Reiterates “Buy” Rating for Sage Therapeutics, Inc. (SAGE)” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/09/15/suntrust-banks-inc-reiterates-buy-rating-for-sage-therapeutics-inc-sage.html.
Large investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Sage Therapeutics by 10,082.5% during the first quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock valued at $203,482,000 after acquiring an additional 2,835,006 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new position in shares of Sage Therapeutics during the first quarter valued at $35,493,000. Marshall Wace North America L.P. bought a new position in shares of Sage Therapeutics during the first quarter valued at $35,493,000. Point72 Asset Management L.P. raised its stake in shares of Sage Therapeutics by 512.9% during the first quarter. Point72 Asset Management L.P. now owns 395,300 shares of the biopharmaceutical company’s stock valued at $28,094,000 after acquiring an additional 330,800 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Sage Therapeutics by 10.8% during the first quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock valued at $191,269,000 after acquiring an additional 261,759 shares during the last quarter.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.